Back to Journals » ImmunoTargets and Therapy » Volume 6

ImmunoTargets and Therapy

ISSN: 2253-1556

Archive: Volume 6, 2017

The current status of immunobased therapies for metastatic renal-cell carcinoma

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS

ImmunoTargets and Therapy 2017, 6:83-93

Published Date: 5 December 2017

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy

Xu A, Freywald A, Xie Y, Li Z, Xiang J

ImmunoTargets and Therapy 2017, 6:39-49

Published Date: 15 June 2017

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG

ImmunoTargets and Therapy 2017, 6:11-16

Published Date: 20 March 2017

First-line treatment of metastatic melanoma: role of nivolumab

Force J, Salama AK

ImmunoTargets and Therapy 2017, 6:1-10

Published Date: 13 February 2017